Last Updated: August 8, 2026

Details for Patent: 8,580,858

Name: Drug Patent Intelligence for US Patent 8580858
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,580,858

Title:	Compositions for the treatment of CNS-related conditions
Abstract:	The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
Inventor(s):	Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
Assignee:	Adamas Pharmaceuticals Inc , Adamas Pharma LLC
Application Number:	US13/725,246
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,580,858
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;
Patent landscape, scope, and claims:	error: insufficient information More… ↓ ⤷ Start Trial

Drugs Protected by US Patent 8,580,858

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,580,858

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E481096	⤷ Start Trial
Australia	2005209310	⤷ Start Trial
Australia	2005215767	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.